Takeda gets European Commission approval for Fruzaqla for previously treated metastatic Colorectal cancer Ruchika Sharma23 Jun 2024 12:00 PM ISTFRUZAQLA is a selective oral inhibitor of all three VEGF receptors (-1, -2 and -3). VEGFR inhibitors play a pivotal role in blocking tumor...
USFDA approves Takeda Fruzaqla for previously treated Metastatic Colorectal Cancer Ruchika Sharma10 Nov 2023 1:51 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for...
Failed Drugs, Loss of Patent: Japanese drugmaker Takeda slashes full-year profit forecast by 36 percent Ruchika Sharma26 Oct 2023 3:21 PM ISTTokyo: Japan's biggest drugmaker Takeda Pharmaceutical has slashed its full-year profit forecast by 36% as it contends with disappointments in...
Takeda, HUTCHMED gets EMA validation for marketing authorization application for Fruquintinib for Metastatic Colorectal Cancer Ruchika Sharma18 Jun 2023 12:15 PM ISTOsaka: Takeda and HUTCHMED (China) Limited have announced that the European Medicines Agency (EMA) has validated and accepted for regulatory...
Medical Bulletin 17/June/2023 Roshni Dhar17 Jun 2023 3:30 PM ISTHere are the top medical news for the day: Sickle cell disease is 11 times more deadly than previously recordedA new study suggests the number of...
New treatment option for metastatic colorectal cancer prolongs survival Roshni Dhar17 Jun 2023 9:00 AM ISTA new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options. Results from an international...
Takeda to acquire exclusive worldwide (ex-China) license of HUTCHMED's Fruquintinib Ruchika Sharma26 Jan 2023 3:30 PM ISTUnder the terms of the agreement, Takeda will receive an exclusive worldwide license to develop and commercialize fruquintinib in all indications and...
Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib Isra Zaman13 Sept 2022 9:30 AM ISTResearchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly...
